- Publication explores structure-activity
relationships (“SAR”) of a broad range of 2C-X analogs -
- Innovative research led to the discovery of
CYB210010, a potent and long-acting serotonin 5-HT2 receptor
agonist with favorable pharmacokinetic properties -
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin”
or the “Company”), a clinical-stage biopharmaceutical
company committed to revolutionizing mental healthcare by
developing new and innovative next-generation psychedelic-based
treatment options, today announced that its research manuscript,
entitled “Synthesis and Structure-Activity Relationships of
2,5-dimethoxy-4-substituted phenethylamines and the discovery of
CYB210010: A potent, orally bioavailable and long-acting serotonin
5-HT2 receptor agonist,” has been published in the Journal of
Medicinal Chemistry, a prestigious bi-weekly peer-reviewed
publication.
“We are delighted that our research on phenethylamine serotonin
5-HT2 receptor agonists was published in this important journal,”
said Doug Drysdale, Chief Executive Officer of Cybin. “This study
is an example of our expanding scope of innovative development work
beyond our clinical tryptamine programs. This publication is a
testament not only to our scientific leadership in the field of
5-HT2 receptor agonists, the receptor family believed to mediate
the therapeutic effects of classic psychedelics, but also to the
depth and breadth of our expertise as we continue to advance the
study of the role of next-generation psychedelic-based treatment
options for mental health and neurological disorders.”
“In the past decade, there has been a revival of interest in
serotonin (5-HT)-based psychedelics as pharmacotherapeutics for
neuropsychiatric disorders,” said Geoff Varty, Ph.D., Head of
R&D of Cybin. “Given the clinical potential of 2C-X
phenethylamines, our studies explored the SARs of a broad range of
2C-X analogs, focusing on 4-thio derivatives, to identify novel
5-HT2 receptor ligands with unique pharmacodynamic (“PD”) and
pharmacokinetic (“PK”) properties. We synthesized 39 proprietary
4-substituted-2,5-dimethoxyphenethylamines and these
phenethylamines were profiled for their ability to interact with
the serotonin system and to induce psychedelic-like effects in
preclinical models. This research led to the discovery of
CYB210010, a potent and long-acting serotonin 5-HT2 receptor
agonist with favorable PK and PD properties,” concluded Dr.
Varty.
Future investigations will focus on the development of CYB210010
and related molecules as novel therapeutics for psychiatric and
neurological disorders with unmet needs.
Click here to view the full publication.
Title: Synthesis and Structure-Activity Relationships of
2,5-dimethoxy-4-substituted phenethylamines and the discovery of
CYB210010: A potent, orally bioavailable and long-acting serotonin
5-HT2 receptor agonist
Authors: Geoff Varty, Clint Canal, Tina Mueller, Josh
Hartsel, Richa Tyagi, Ken Avery, Mike Morgan, Amy Reichelt, Pradip
Pathare, Erik Stang, Mike Palfreyman, Alex Nivorozhkin
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission
to create safe and effective psychedelic-based therapeutics to
address the large unmet need for new and innovative treatment
options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported
by a network of world-class partners and internationally recognized
scientists aimed at progressing proprietary drug discovery
platforms, innovative drug delivery systems, and novel formulation
approaches and treatment regimens. The Company is currently
developing CYB003, a proprietary deuterated psilocybin analog for
the treatment of major depressive disorder and CYB004, a
proprietary deuterated DMT molecule for generalized anxiety
disorder and has a research pipeline of investigational
psychedelic-based compounds.
Headquartered in Canada and founded in 2019, Cybin is
operational in Canada, the United States, the United Kingdom, the
Netherlands and Ireland. For company updates and to learn more
about Cybin, visit www.cybin.com or follow the team on X, LinkedIn,
YouTube and Instagram.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company
are forward-looking statements and are prospective in nature.
Forward-looking statements are not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “may”, “should”, “could”, “intend”,
“estimate”, “plan”, “anticipate”, “expect”, “believe” or
“continue”, or the negative thereof or similar variations.
Forward-looking statements in this news release include statements
regarding the development of CYB210010; and the Company’s
proprietary drug discovery platforms, innovative drug delivery
systems, novel formulation approaches and treatment regimens for
mental health conditions.
These forward-looking statements are based on reasonable
assumptions and estimates of management of the Company at the time
such statements were made. Actual future results may differ
materially as forward-looking statements involve known and unknown
risks, uncertainties, and other factors which may cause the actual
results, performance, or achievements of the Company to materially
differ from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors, among other things, include: fluctuations in general
macroeconomic conditions; fluctuations in securities markets;
expectations regarding the size of the psychedelics market; the
ability of the Company to successfully achieve its business
objectives; plans for growth; political, social and environmental
uncertainties; employee relations; the presence of laws and
regulations that may impose restrictions in the markets where the
Company operates; implications of disease outbreaks on the
Company's operations; and the risk factors set out in each of the
Company's management's discussion and analysis for the three and
nine month periods ended December 31, 2023 and the Company’s annual
information form for the year ended March 31, 2023, which are
available under the Company's profile on www.sedarplus.ca and with
the U.S. Securities and Exchange Commission on EDGAR at
www.sec.gov. Although the forward-looking statements contained in
this news release are based upon what management of the Company
believes, or believed at the time, to be reasonable assumptions,
the Company cannot assure shareholders that actual results will be
consistent with such forward-looking statements, as there may be
other factors that cause results not to be as anticipated,
estimated or intended. Readers should not place undue reliance on
the forward-looking statements and information contained in this
news release. The Company assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or
other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about
Cybin’s proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds. The efficacy
of such products has not been confirmed by approved research. There
is no assurance that the use of psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds can diagnose,
treat, cure or prevent any disease or condition. Rigorous
scientific research and clinical trials are needed. Cybin has not
conducted clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin’s
performance and operations.
Neither the Cboe Canada, nor the NYSE American LLC stock
exchange have approved or disapproved the contents of this news
release and are not responsible for the adequacy and accuracy of
the contents herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240418413250/en/
Investors & Media: Gabriel Fahel Chief Legal Officer
Cybin Inc. 1-866-292-4601 irteam@cybin.com – or –
media@cybin.com